Protagonist Therapeutics Inc

6 de ago. de 2026, 19:52 UTC

Protagonist Therapeutics shares rise following multiple price target upgrades, including Citi's increase to $175, amid positive sentiment on drug approvals and pharmacokinetic data.

5 de ago. de 2026, 22:02 UTC

Protagonist Therapeutics reports Q2 net income of $162.8 million, up from a loss last year. Shares are higher in after-market trading following the results.

4 de ago. de 2026, 21:03 UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, supported by their position above the 20-day moving average. No specific news was identified.

3 de ago. de 2026, 19:36 UTC

Protagonist Therapeutics Inc shares are lower today, continuing a decline since Friday. The stock is near the lower end of its one-month range.

31 de jul. de 2026, 19:36 UTC

Protagonist Therapeutics Inc is lower today amid broader weakness in the Biotechnology sector. Earlier in the session, shares pulled back from a high.

30 de jul. de 2026, 21:02 UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, amid notable volatility and significant price swings since Thursday's close.

29 de jul. de 2026, 19:43 UTC

Protagonist Therapeutics Inc shares are lower amid market volatility following the Federal Reserve's decision to maintain interest rates, reflecting broader uncertainty.

28 de jul. de 2026, 21:01 UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, maintaining a notable gain since Tuesday's close, despite no specific news identified.

27 de jul. de 2026, 20:02 UTC

Protagonist Therapeutics shares are lower despite Jefferies raising its price target to $171 and Cowen increasing its peak royalty revenue forecast to $1.4 billion.

22 de jul. de 2026, 19:42 UTC

Protagonist Therapeutics Inc is trading lower today, continuing a decline since Tuesday amid rising crude oil prices and market tensions related to Iran.

21 de jul. de 2026, 19:06 UTC

Protagonist Therapeutics Inc shares are higher today, continuing an upward trend since Monday's close, supported by gains in the semiconductor sector.

20 de jul. de 2026, 19:41 UTC

Protagonist Therapeutics shares are lower as analysts raise price targets and revenue forecasts ahead of Q2 earnings, despite a noted 0% probability of success for PN-881.